US008569369B2

(12) **United States Patent**
Kramer et al.

(10) **Patent No.: US 8,569,369 B2**
(45) **Date of Patent: *Oct. 29, 2013**

(54) **AMINO ACID COMPOUNDS**

(75) Inventors: **Ronald Kramer**, Phoenix, AZ (US); **Alexander Nikolaidis**, New Kallikratia (GR)

(73) Assignee: **Thermolife International, LLC**, Phoenix, AZ (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **13/468,231**

(22) Filed: **May 10, 2012**

(65) **Prior Publication Data**

US 2012/0220643 A1 Aug. 30, 2012

Related U.S. Application Data

(63) Continuation-in-part of application No. 12/946,153, filed on Nov. 15, 2010, now Pat. No. 8,178,572, which is a continuation of application No. 12/336,938, filed on Dec. 17, 2008, now Pat. No. 8,034,836, which is a continuation of application No. 11/950,273, filed on Dec. 4, 2007, now Pat. No. 7,777,074.

(60) Provisional application No. 60/973,229, filed on Sep. 18, 2007.

(51) **Int. Cl.**
A61K 31/205 (2006.01)

(52) **U.S. Cl.**
USPC **514/556**

(58) **Field of Classification Search**
USPC 514/556
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,886,040	A	5/1975	Chihata et al.	
3,997,659	A	12/1976	Knohl et al.	
4,146,611	A	3/1979	Ondetti et al.	
4,379,177	A	4/1983	McCoy et al.	
4,743,614	A	5/1988	Terano et al.	
5,500,436	A	3/1996	Schonafinger et al.	
5,679,704	A	10/1997	Schonafinger et al.	
7,235,237	B2	6/2007	Loscalzo et al.	
8,034,836	B2	10/2011	Kramer et al.	
8,048,921	B2 *	11/2011	Kramer et al.	514/556
2005/0287210	A1	12/2005	Ron	
2005/0288372	A1	12/2005	Ron	
2005/0288373	A1	12/2005	Ron	
2006/0029668	A1	2/2006	Ron	
2006/0182815	A1	8/2006	Gladwin et al.	
2007/0154569	A1	7/2007	Gladwin et al.	

FOREIGN PATENT DOCUMENTS

CN	1631539	6/2005
EP	1336602	8/2003
GB	2354441	3/2001
WO	WO2006124161	4/2005

OTHER PUBLICATIONS

Jablecka et al., Med Sci Monit 10(I):CR29-32 (2004).
Maynard et al., J. Nutr. 131:287-290 (2001).
Ruel et al., J. Thorac Cardiovasc. Surg 135:762-77, 2008.
Rytlewski et al., European Journal of Obstetrics & Gynecology and Reproductive Biology 138:23-28 (2008).
Schwedheim et al., Br J Clin Pharmacol 65(1):51-59 (2007).
Smith et al., J. Thorac Cardiovasc. Surg 132:58-65 (2006).
Rytlewski et al., Eur J. Clin Invest 35 (1):32-37 (2005).
Ming et al., Circulation 110:3708-3714 (2004).
Romero et al., Cardiovascular Drug Reviews 24(3-4):275-290 (2006).
Oka et al., Vasc Med 10:265-274 (2005).
Hayashi et al., PNAS 102(38):13681-13686 (2005).
Grasemann et al., Eur Respir J 25:62-68 (2005).
Boger, J. Nutr 137:1650S-1655S (2007).
Beghetti et al., J. Thorac Cardiovasc. Surg 132(6):1501-1502 (2006).
Larsen et al., B. Acta Physiol 191(1):59-66 (2007).
Berge, Journal of Pharmaceutical Sciences, Jan. 1977, vol. 66, No. 1.
Takahashi et al., "Characterization of the influence of nitric oxide donors on intestinal absorption of macromolecules," International Journal of Pharmaceutics vol. 286:89-97 (2004).
Fetih et al., "Nitric oxide donors can enhance the intestinal transport and absorption of insulin and [Asu 1,7]-eel calcitonin in rats," Journal of Controlled Release vol. 106:287-297 (2005).
Fetih et al., "Excellent Absorption Enhancing Characteristics of NO Donors for Improving the Intestinal Absorption of Poorly Absorbable Compound Compared with Conventional Absorption Enhancers," Drug Metab. Pharmacokinet. vol. 21(3):222-229 (2006).
Aniya et al. , "Evaluation of Nitric Oxide Formation from Nitrates in Pig Coronary Arteries," Jpn. J. Pharmacal. vol. 71: 101-107 (1996).
T.F. Luscher, "Endogenous and exogenous nitrates and their role in myocardial ischaemia," Br. J. Clin. Pharmacol. vol. 34:29S-35S (1992).
Shiraki et al., "The hypotensive mechanisms of the new anti-anginal drug, N-(2-Hydroxyethyl) Nicotinamide Nitrate (SG-75) in beagle dogs," Japan. J. Pharmacol. vol. 31:921-929 (1981).
CFIndustries, "Material Safety Data Sheet for Urea Ammonium Nitrate Solution (UAN)," available at www.cfindustries.com/pdf/UANMSDS.pdf Oct. 25, 2006.
Slart et al., "Nitrate Administration Increases Blood Flow in Dysfunctional but Viable Myocardium, Leading to Improved Assessment of Myocardial Viability: A PET Study," J. Nucl. Med. vol. 47: 1307-1311 (2006).
Fayers et al., "Nitrate tolerance and the links with endothelial dysfunction and oxidative stress," Blackwell Publishing Ltd Br. J. Clin. Pharmacol. vol. 56:620-628 (2003).
Harm J. Knot. "Nitrate Tolerance in Hypertension New Insight Into a Century-Old Problem," Circulation Research vol. 93:799-801 (2003).
Schulz et al., "Functional and Biochemical Analysis of Endothelial (Dys)function and NO/cGMP Signaling in Human Blood Vessels With and Without Nitroglycerin Pretreatment," Circulation Research vol. 105:1170-1175 (2002).

(Continued)

Primary Examiner — Rei-tsang Shiao
(74) *Attorney, Agent, or Firm* — Booth Udall Fuller, PLC

(57) **ABSTRACT**

A method for increasing the vasodilative characteristics of amino acids in a human or animal is disclosed. The method includes administering to the human or animal a pharmaceutically effective amount of an amino acid compound consisting essentially of a nitrate or nitrite of an amino acid selected from the group consisting of Aspartic Acid, Cysteine, Glycine, Lysine, Methionine, Proline, Tyrosine, Phenylalanine, Carnitine, Taurine, and Betaine.

1 Claim, No Drawings